Functional significance of S6K overexpression in meningioma progression

Annals of Neurology

Volumn 56, Issue 2, 2004, Pages 295-298

  Surace, Ezequiel I ^a   Lusis, Eriks ^a   Haipek, Carrie A ^a   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

S6 KINASE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER THERAPY; CELL ADHESION; CELL GROWTH; CELL MOTILITY; CHROMOSOME 17; CONTROLLED STUDY; GENE AMPLIFICATION; GENE LOCATION; GENE OVEREXPRESSION; GENE TARGETING; HEREDITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MENINGIOMA; PRIORITY JOURNAL; S6K GENE;

ANIMALS; BLOTTING, WESTERN; CELL COUNT; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES; RNA, MESSENGER; TIME FACTORS; TRANSFECTION;

EID: 3843142774     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20201     Document Type: Article

References (19)

1. Louis DN, Scheithauer BW, Budka H, et al. Meningiomas. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumors. Pathology and Genetics: Tumors of the Central Nervous System. Lyon: IARC Press, 2000: 176-184.
2. Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6:180-184.
3. Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000;9:1495-1500.
4. Kalamarides M, Niwa-Kawakita M, Leblois H, et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002;16:1060-1065.
5. Perry A, Cai DX, Scheithauer BW, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000;59:872-879.
6. Gutmann DH, Hirbe AC, Huang ZY, Haipek CA. The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis 2001;8:266-278.
7. Buschges R, Ichimura K, Weber RG, et al. Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol 2002;12:145-153.
8. Cai DX, Banerjee R, Scheithauer BW, et al. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 2001;60:628-636.
9. Lamszus K, Kluwe L, Matschke J, et al. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 1999;110:103-110.
10. Weber RG, Bostrom J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 1997;94:14719-14724.
11. Perry A, Banerjee R, Lohse CM, et al. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 2002;12:183-190.
12. INK4c) in atypical and anaplastic meningiomas. Am J Pathol 2001;159:66l-669.
13. Peters N, Wellenreuther R, Rollbrocker B, et al. Analysis of the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol 1998;24:3-8.
14. Cai DX, James CD, Scheithauer BW, et al. PS6K amplification characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol 2001;115:213-218.
15. Couch FJ, Wang XY, Wu GJ, et al. Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res 1999;59:1408-1411.
16. Watanabe T, Imoto I, Kosugi Y, et al. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 2001;81:172-177.
17. Iliopoulos O, Kibel A, Gray S, et al. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995; 1:822-826.
18. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115: 577-590.
19. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003;63:5173-5177.